Current Trial Listing

Condition	Trial Name	Sponsor
Non-Small Cell Lung Cancer	AndroMETa-Lung-536: Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC	AbbVie
Non-Small Cell Lung Cancer	ARTEMIA: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor	OSE Immunotherapeutics
Breast Cancer	ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer	Gilead Sciences, Inc.
Breast Cancer	BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer	BriaCell Therapeutics Corporation
Non-Small Cell Lung Cancer	COPERNICUS: A Phase 2b, Open-Label, Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment	Janssen Research & Development, LLC
Small Cell Lung Cancer	DeLLphi-312: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer	Amgen
Breast Cancer	First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer	Regor Pharmaceuticals Inc.
Chemotherapy Induced Peripheral Neuropathy	IMPACT: Lilac Boot and Glove Device for the Prevention of Chemotherapy Induced Peripheral Neuropathy	Luminate Medical, Inc.
Colorectal Cancer	INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer	Hoffmann-La Roche
Breast Cancer	MoonROSE: CDK2/4/6 Inhibitor GDC-4198 in Combination with Giredestrant for Patients with ER+, HER2- Metastatic Breast Cancer After Treatment with a CDK4/6 Inhibitor	Genentech, Inc.
Colorectal Cancer	OrigAMI-2: Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Cancer	Janssen Research & Development, LLC
Colorectal Cancer	OrigAMI-3: Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer	Janssen Research & Development, LLC
Advanced Solid tumors	Phase 1 Study of SGN-B6A in Advanced Solid Tumors	Seagen Inc.
Chronic Myeloid Leukemia	POLARIS-2: Study of Olverembatinib (HQP1351) in Patients With CP-CML	Ascentage Pharma Group Inc.
Solid Tumors or Multiple Myeloma	QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma	Nammi Therapeutics Inc
Cancer Diagnosis	[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients	Memorial Sloan Kettering Cancer Center
Various Indications	[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx)	Precision for Medicine
Solid Tumors	[Sample Collection] Collection and Distribution of Biofluids for Research Purposes	Bluestar Genomics
Solid Tumors	[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2)	Exact Sciences Thrive LLC
Various Indications	[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035)	SERATRIALS, LLC.
Solid Tumors	[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening	Freenome Holdings Inc.
Pancreatic Cancer	TRIDENT: Relacorilant in Combination with Chemotherapy for the First Line Treatment of Pancreatic Cancer	Corcept Therapeutics

Need More Information?

Our team is here to help answer your questions and guide you through your options.

Call (855) 528-7322 Request Appointment